Novartis scoops up UK biotech Myricx in $1.5 billion cancer push

Novartis AG NVS has agreed to acquire privately held U.K. biotechnology company Myricx Bio in a deal valued at up to $1.5 ...
The Manila Times

PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset

PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class ...
The Next Web

Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class

Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for antibody-drug conjugates.

Aussie super funds hit the jackpot in $2b UK biotech deal

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...
The Manila Times

Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform

ADC payload with a differentiated mechanism of actionCombines oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumour ...
Pharmabiz

US FDA grants breakthrough therapy designation for INTENT Biologics’ PEP Biologic to treat diabetic foot ulcers

US FDA grants breakthrough therapy designation for INTENT Biologics’ PEP Biologic to treat diabetic foot ulcers: Rochester, Minnesota Friday, July 3, 2026, 09:00 Hrs [IST] INTEN ...

Is Septerna, Inc. (SEPN) Stock a Biotech Opportunity With a Potential First-in-Class Hypoparathyroidism Treatment?

Septerna, Inc. (NASDAQ:SEPN) is one of the best up and coming stocks on our list. TheFly reported on June 11 that Guggenheim ...
Las Vegas Sun

Permeasis Therapeutics and The Ohio State University Publish Foundational Research on Intracellular Delivery Technology in ACS Chemical Biology

Permeasis Therapeutics (“Permeasis”), a biotechnology company developing intracellular biologics enabled by its proprietary Membrane Translocation Domain (MTD) platform announced the publication of ...

INTENT Biologics Receives FDA Breakthrough Therapy Designation for PEP Biologic™ for its Phase 3 Ready Flagship Indication

INTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the ...
Labiotech.eu

Prague: The up-and-coming biotech hub in Central Europe

Discover Prague's biotech hub, now viewed as the primary ‘entry gateway’ into the wider Central and Eastern European ...
Pharmabiz

Talawar Therapeutics and JATT II enter definitive business combination agreement to create publicly listed biotechnology company

Talawar Therapeutics and JATT II enter definitive business combination agreement to create publicly listed biotechnology company: New York Wednesday, July 1, 2026, 16:00 Hrs [IST] ...

Salipro Biotech Announces Publication in Nature Scientific Reports on Expanding DEL Screening to Membrane Proteins

Study demonstrates application of DNA-Encoded Library screening to native-like membrane protein targets with the ...